ImportantUpdates
Marksans Pharma reports full-year consolidated revenue up 12.5% to ₹2,950.94 Cr, with PAT rising 9.8% to ₹420.06 Cr.
Marksans Pharma LimitedMARKSANS · Filed with the exchange
EPS grew to ₹9.22. The company established new wholly-owned subsidiaries in Ireland and Canada, granted 400,000 employee stock options, and declared a final dividend of ₹0.90 per share.
No comments yet. Be the first.